Each film coated tablet contains:
Levocetirizine Dihydrochloride 5 mg
MODE OF ACTION OF LEVOCETRIZINE (NASAL AREA)
Levocetrizine (Cetrilive) H1 receptor, by blocking H1 receptor Cetriliv reduces allergic manifestation
Cmax - 27µg/ml Tmax - .75 hours
½ life - 7 hours PPB - 94.8% - 95%
The distribution of levocetrizine is restrictive. It is even lower than that usually reported for cetrizine which is lower than that of the other antihistamines of the second generation.
Levocetrizine may decrease distribution of the drug into the CNS, resulting in reduced potential for adverse CNS effects.
Does not cross blood brain barrier.
Levocetrizine is very poorly metabolized. The cumulative 48 hr excretion as parent compound accounted for 85.8% of the oral dose. No first pass metabolism.
83.5% drug is excreted through urine and 14.5% is excreted with feces.
• Seasonal allergic rhinitis, perennial allergic rhinitis
• Chronic idiopathic urticaria
• Atopic eczema and contact dermatitis
• Ocular symptoms
• Other indications – reaction to drugs, food and insect bite
• Nasal congestion